Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emanuela Ferraro

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
Future Oncology (London, England)|July 11, 2015
Sorafenib: 10 years after the first pivotal trialGennaro Gadaleta-Caldarola, Stefania Infusino, Rosa Divella, et al.
Oncology|July 24, 2018
Predictive Factors of Eribulin Activity in Metastatic Breast Cancer PatientsRita De Sanctis, Elisa Agostinetto, Giovanna Masci, et al.
JAMA Network Open|January 31, 2025
Survival Among Patients With ERBB2-Positive Metastatic Breast Cancer and Central Nervous System DiseaseEmanuela Ferraro, Anne S Reiner, Rabih Bou Nassif, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|August 29, 2025
<i>Bordetella pertussis</i> in hospitalised children and adolescents: the impact of vaccination delay, Tuscany, Italy, 2016 to 2024Francesco Nieddu, Francesca Quaranta, Marina Vignoli, et al.
Breast Cancer Research and Treatment|July 15, 2021
Does preoperative MRI accurately stratify early-stage HER2 + breast cancer patients to upfront surgery vs neoadjuvant chemotherapy?Astrid Botty van den Bruele, Emanuela Ferraro, Varadan Sevilimedu, et al.
Expert Opinion on Pharmacotherapy|May 22, 2026
Oral selective estrogen receptor degraders (SERDs) for the treatment of hormone receptor-positive, HER2-negative breast cancer title: oral selective estrogen receptor degraders (SERDs) for the treatment of hormone receptor-positive, HER2-negative breast cancerJulian David Etessami, Carmine Valenza, Pier Paolo Maria Berton Giachetti, et al.
Vaccines|February 26, 2026
Harnessing Vaccines in the Treatment of Solid Tumors: Advances, Challenges, and Future DirectionsJorge Iranzo, Edoardo Giordano, Renato Maria Marsicano, et al.
Human Vaccines & Immunotherapeutics|June 17, 2025
Serotype 3 invasive pneumococcal disease in Tuscany across the eras of conjugate vaccines (2005-2024) and anthropic-driven respiratory virus fluctuationsLorenzo Lodi, Francesco Catamerò, Walter Maria Sarli, et al.
European Journal of Pediatrics|November 3, 2025
Public health impact of nirsevimab and reduction of RSV hospitalisation in all infants: early real-world data from Tuscany (Italy) in the 2024-25 RSV seasonFrancesco Nieddu, Marina Vignoli, Emanuela Ferraro, et al.
Nature Communications|November 19, 2021
HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathwayAlison E Smith, Emanuela Ferraro, Anton Safonov, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Future Oncology (London, England)|July 11, 2015
Sorafenib: 10 years after the first pivotal trialGennaro Gadaleta-Caldarola, Stefania Infusino, Rosa Divella, et al.
Oncology|July 24, 2018
Predictive Factors of Eribulin Activity in Metastatic Breast Cancer PatientsRita De Sanctis, Elisa Agostinetto, Giovanna Masci, et al.
JAMA Network Open|January 31, 2025
Survival Among Patients With ERBB2-Positive Metastatic Breast Cancer and Central Nervous System DiseaseEmanuela Ferraro, Anne S Reiner, Rabih Bou Nassif, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|August 29, 2025
<i>Bordetella pertussis</i> in hospitalised children and adolescents: the impact of vaccination delay, Tuscany, Italy, 2016 to 2024Francesco Nieddu, Francesca Quaranta, Marina Vignoli, et al.
Breast Cancer Research and Treatment|July 15, 2021
Does preoperative MRI accurately stratify early-stage HER2 + breast cancer patients to upfront surgery vs neoadjuvant chemotherapy?Astrid Botty van den Bruele, Emanuela Ferraro, Varadan Sevilimedu, et al.
Expert Opinion on Pharmacotherapy|May 22, 2026
Oral selective estrogen receptor degraders (SERDs) for the treatment of hormone receptor-positive, HER2-negative breast cancer title: oral selective estrogen receptor degraders (SERDs) for the treatment of hormone receptor-positive, HER2-negative breast cancerJulian David Etessami, Carmine Valenza, Pier Paolo Maria Berton Giachetti, et al.
Vaccines|February 26, 2026
Harnessing Vaccines in the Treatment of Solid Tumors: Advances, Challenges, and Future DirectionsJorge Iranzo, Edoardo Giordano, Renato Maria Marsicano, et al.
Human Vaccines & Immunotherapeutics|June 17, 2025
Serotype 3 invasive pneumococcal disease in Tuscany across the eras of conjugate vaccines (2005-2024) and anthropic-driven respiratory virus fluctuationsLorenzo Lodi, Francesco Catamerò, Walter Maria Sarli, et al.
European Journal of Pediatrics|November 3, 2025
Public health impact of nirsevimab and reduction of RSV hospitalisation in all infants: early real-world data from Tuscany (Italy) in the 2024-25 RSV seasonFrancesco Nieddu, Marina Vignoli, Emanuela Ferraro, et al.
Nature Communications|November 19, 2021
HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathwayAlison E Smith, Emanuela Ferraro, Anton Safonov, et al.
Pageof 4